98 related articles for article (PubMed ID: 25850059)
1. Genetic variation and alternative splicing.
Estivill X
Nat Biotechnol; 2015 Apr; 33(4):357-9. PubMed ID: 25850059
[No Abstract] [Full Text] [Related]
2. RNA. Prescribing splicing.
Guigó R; Valcárcel J
Science; 2015 Jan; 347(6218):124-5. PubMed ID: 25574005
[TBL] [Abstract][Full Text] [Related]
3. RNA splicing. The human splicing code reveals new insights into the genetic determinants of disease.
Xiong HY; Alipanahi B; Lee LJ; Bretschneider H; Merico D; Yuen RK; Hua Y; Gueroussov S; Najafabadi HS; Hughes TR; Morris Q; Barash Y; Krainer AR; Jojic N; Scherer SW; Blencowe BJ; Frey BJ
Science; 2015 Jan; 347(6218):1254806. PubMed ID: 25525159
[TBL] [Abstract][Full Text] [Related]
4. Genome-Wide Annotation of circRNAs and Their Alternative Back-Splicing/Splicing with CIRCexplorer Pipeline.
Dong R; Ma XK; Chen LL; Yang L
Methods Mol Biol; 2019; 1870():137-149. PubMed ID: 30539552
[TBL] [Abstract][Full Text] [Related]
5. Targeting splicing in spinal muscular atrophy.
Burnett BG; Sumner CJ
Ann Neurol; 2008 Jan; 63(1):3-6. PubMed ID: 18232015
[No Abstract] [Full Text] [Related]
6. [Aberrant mRNA splicing in human diseases].
Imaizumi K
Tanpakushitsu Kakusan Koso; 2006 Nov; 51(14 Suppl):2287-93. PubMed ID: 17471954
[No Abstract] [Full Text] [Related]
7. Spinal muscular atrophy: SMN2 pre-mRNA splicing corrected by a U7 snRNA derivative carrying a splicing enhancer sequence.
Marquis J; Meyer K; Angehrn L; Kämpfer SS; Rothen-Rutishauser B; Schümperli D
Mol Ther; 2007 Aug; 15(8):1479-86. PubMed ID: 17505471
[TBL] [Abstract][Full Text] [Related]
8. Nucleic Acid-Targeted Small Molecules have Therapeutic Potential in the Treatment of Spinal Muscular Atrophy: Small-molecule drugs that can selectively bind RNA and modulate pre-mRNA splicing have potential as a treatment strategy for human disease, including spinal muscular atrophy.
Am J Med Genet A; 2018 Aug; 176(8):1698-1699. PubMed ID: 30136439
[No Abstract] [Full Text] [Related]
9. 5-(N-ethyl-N-isopropyl)-amiloride enhances SMN2 exon 7 inclusion and protein expression in spinal muscular atrophy cells.
Yuo CY; Lin HH; Chang YS; Yang WK; Chang JG
Ann Neurol; 2008 Jan; 63(1):26-34. PubMed ID: 17924536
[TBL] [Abstract][Full Text] [Related]
10. A negative element in SMN2 exon 7 inhibits splicing in spinal muscular atrophy.
Kashima T; Manley JL
Nat Genet; 2003 Aug; 34(4):460-3. PubMed ID: 12833158
[TBL] [Abstract][Full Text] [Related]
11. Antisense methods to modulate pre-mRNA splicing.
Seo J; Ottesen EW; Singh RN
Methods Mol Biol; 2014; 1126():271-83. PubMed ID: 24549671
[TBL] [Abstract][Full Text] [Related]
12. Identification of a one-base germline deletion (codon 888 del C) and an intron splice acceptor site polymorphism in hMSH2.
Swensen J; Lewis CM; Cannon-Albright LA
Hum Mutat; 1997; 10(1):80-1. PubMed ID: 9222765
[No Abstract] [Full Text] [Related]
13. Identification of a splicing enhancer in MLH1 using COMPARE, a new assay for determination of relative RNA splicing efficiencies.
Xu DQ; Mattox W
Hum Mol Genet; 2006 Jan; 15(2):329-36. PubMed ID: 16357104
[TBL] [Abstract][Full Text] [Related]
14. Gene symbol: hMLH1. Disease: Hereditary nonpolyposis colorectal cancer.
Sun MH; Cai Q; Fu G; Ren S; Mo S; Xu Y; Ding C; Zhang T; Zhu X; Xu X; Min D; Cai S; Luo D; Shi Y; Shi D
Hum Genet; 2004 Mar; 114(4):411. PubMed ID: 15046112
[No Abstract] [Full Text] [Related]
15. Gene symbol: hMLH1. Disease: Hereditary nonpolyposis colorectal cancer.
Sun MH; Cai Q; Fu G; Ren S; Mo S; Xu Y; Ding C; Zhang T; Zhu X; Xu X; Min D; Cai S; Luo D; Shi Y; Shi D
Hum Genet; 2004 Mar; 114(4):411. PubMed ID: 15046110
[No Abstract] [Full Text] [Related]
16. Translational development of splice-modifying antisense oligomers.
Fletcher S; Bellgard MI; Price L; Akkari AP; Wilton SD
Expert Opin Biol Ther; 2017 Jan; 17(1):15-30. PubMed ID: 27805416
[TBL] [Abstract][Full Text] [Related]
17. Whole-transcriptome sequencing in blood provides a diagnosis of spinal muscular atrophy with progressive myoclonic epilepsy.
Kernohan KD; Frésard L; Zappala Z; Hartley T; Smith KS; Wagner J; Xu H; McBride A; Bourque PR; Consortium CRC; Bennett SAL; Dyment DA; Boycott KM; Montgomery SB; Warman Chardon J
Hum Mutat; 2017 Jun; 38(6):611-614. PubMed ID: 28251733
[TBL] [Abstract][Full Text] [Related]
18. Is spinal muscular atrophy the result of defects in motor neuron processes?
Briese M; Esmaeili B; Sattelle DB
Bioessays; 2005 Sep; 27(9):946-57. PubMed ID: 16108074
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics, pharmacodynamics, and efficacy of a small-molecule SMN2 splicing modifier in mouse models of spinal muscular atrophy.
Zhao X; Feng Z; Ling KK; Mollin A; Sheedy J; Yeh S; Petruska J; Narasimhan J; Dakka A; Welch EM; Karp G; Chen KS; Metzger F; Ratni H; Lotti F; Tisdale S; Naryshkin NA; Pellizzoni L; Paushkin S; Ko CP; Weetall M
Hum Mol Genet; 2016 May; 25(10):1885-1899. PubMed ID: 26931466
[TBL] [Abstract][Full Text] [Related]
20. [The role of RNA splicing in the pathogenesis of spinal muscular atrophy and development of its therapeutics].
Sahashi K; Sobue G
Brain Nerve; 2014 Dec; 66(12):1471-80. PubMed ID: 25475034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
